Analysis of alkaline phosphatase and γ-glutamyltransferase after radiofrequency ablation of primary liver cancer: A retrospective study

doi:10.4240/wjgs.v16.i9.2860

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (22)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-4)

Sum=20

Sep 27, 2024 (publication date) through Sep 18, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Sep 27, 2024; 16(9): 2860-2869
Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2860

Analysis of alkaline phosphatase and γ-glutamyltransferase after radiofrequency ablation of primary liver cancer: A retrospective study

Wen-Yu Huang, Sheng Zheng, Dan Zhu, Ying-Lang Zeng, Juan Yang, Xue-Li Zeng, Pei Liu, Shun-Ling Zhang, Ming Yuan, Zhi-Xia Wang

Wen-Yu Huang, Ying-Lang Zeng, Department of Tumor and Vascular Interventional Therapy, Xiamen Humanity Hospital, Xiamen 361000, Fujian Province, China

Sheng Zheng, Department of Gastroenterology, The Third People's Hospital of Yunnan Province, Kunming 650011, Yunnan Province, China

Dan Zhu, Medical Imaging Center, Qian Wei Hospital of Jilin Province, Changchun 130000, Jilin Province, China

Juan Yang, Department of Science and Education, The Third People's Hospital of Yunnan Province, Kunming 650011, Yunnan Province, China

Xue-Li Zeng, Pei Liu, Shun-Ling Zhang, Graduate School of Clinical Medicine, Dali University, Dali 671000, Yunnan Province, China

Ming Yuan, Department of Hepatobiliary Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong Province, China

Zhi-Xia Wang, Department of Oncology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian 223600, Jiangsu Province, China

Co-first authors: Wen-Yu Huang and Sheng Zheng.

Author contributions: Huang WY and Zheng S contribute equally to this study as co-first authors. Huang WY wrote the manuscript; Zheng S, Zhu D, Zeng YL, Yang J, Zeng X L, Liu P, Zhang SL and Yuan M collected the data; Wang ZX guided the study; all authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

Supported by Yunnan Province High-level Scientific and Technological Talents and Innovation Team Selection Special, No. 202405AC350067; Basic Research Joint Special General Project of Yunnan Provincial Local Universities (Part), No. 202301BA070001-029 and No. 202301BA070001-044; Scientific Research Fund Project of Education Department of Yunnan Province, No. 2023J0926; and The 8th Research Project of Education and Teaching Reform of Dali University (Special Medical Education Reform Project), No. 2022JGYX08-01 and No. 2022JGYX08-02.

Institutional review board statement: This study was approved by the Medical Research Ethics Committee.

Informed consent statement: This study has obtained informed consent and signed treatment consent from patients and their families.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Data sharing statement: Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested. Emails could be sent to the address below to obtain the shared data: wzx1230727@163.com.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Zhi-Xia Wang, MM, Doctor, Department of Oncology, The Affiliated Shuyang Hospital of Xuzhou Medical University, No. 9 Yingbin Avenue, Shucheng Town, Shuyang County, Suqian 223600, Jiangsu Province, China. wzx1230727@163.com

Received: May 10, 2024
Revised: July 29, 2024
Accepted: August 2, 2024
Published online: September 27, 2024
Processing time: 131 Days and 6.4 Hours

Core Tip

Core Tip: Clinical data of patients with primary liver cancer (PLC) treated with radiofrequency ablation (RFA) were retrospectively analyzed to evaluate the changes in alkaline phosphatase (ALP) and γ-glutamyltransferase (GGT) levels before and after treatment. The subjects of this study were PLC patients undergoing RFA. By collecting ALP and GGT detection results at different time points before and after treatment, the dynamic trend and clinical significance of these indicators were analyzed.